Protalix Biother SEC Filings

Welcome to our dedicated page for Protalix Biother SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The SEC filings page for Protalix BioTherapeutics, Inc. (PLX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a NYSE American–listed biopharmaceutical issuer focused on rare disease therapeutics and recombinant proteins produced via its ProCellEx® plant cell-based system, Protalix uses these filings to report material events, financial results, governance decisions and capital markets activities.

Investors can review Form 8-K filings that Protalix has used to announce quarterly financial and business results, clinical and regulatory updates for products such as Elfabrio® and PRX–115, changes in executive leadership, entry into or amendments of material agreements, and outcomes of legal or stockholder matters. Other SEC reports, including annual and quarterly reports, provide detailed discussions of revenue from sales of Elfabrio and Elelyso®, collaboration structures with partners like Chiesi, Pfizer and Fiocruz, and the status of development programs such as PRX–119.

For those monitoring corporate finance and ownership, this page also surfaces filings related to equity offerings and governance, such as amendments to at-the-market offering agreements and disclosures about stockholder meetings and executive compensation arrangements. Together, these documents help explain how Protalix funds its operations, manages risk and aligns management incentives.

Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy SEC documents, helping readers quickly understand the implications of Protalix’s 10-K and 10-Q reports, 8-K current reports and other submissions. Real-time updates from EDGAR ensure that new filings appear promptly, while structured access to transaction-related disclosures and governance items supports deeper due diligence on PLX.